Approved Uses Otezla® (apremilast) is a prescription medicine used to treat adult patients with:

  • Plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
  • Active psoriatic arthritis.
  • Oral ulcers associated with Behçet’s Disease.

Enroll in the $0 Co-Pay* Program

Getting an Otezla $0 Co-Pay Card
Did you know the majority of people pay $0 a month for Otezla?

Just fill out and submit the form below—if you’re eligible, you’ll be automatically enrolled and your new $0 Co-Pay Card will be sent to you ready to use.

Prefer to do things over the phone? You can also call 1-844-4OTEZLA (1-844-468-3952) and speak to a SupportPlus™ team member to enroll (available 8 am – 8 pm ET, Monday – Friday).

Start your Co-Pay Program enrollment below

All fields required unless indicated as optional.

Please correct the fields in red.

Gender

Select which applies:

What type of insurance do you use to pay for your Otezla® prescription?

Which condition are you diagnosed with? Check all that apply.

I am a healthcare representative assisting a patient with enrollment

Healthcare Representative:

Patient Information


By providing my phone number, I consent to Amgen calling and texting me at the phone number(s) I have provided with promotional communications relating to Amgen products and services and/or my condition or treatment. Amgen may use automatic dialing machines or artificial or prerecorded messages to contact me and may leave a voicemail or SMS/text message (standard text messaging rates may apply). I understand that I am not required to provide this consent as a condition of purchasing any goods or services. Reply STOP to cancel SMS messages.

Amgen’s Patient Authorization

Amgen’s Privacy Pledge to Patients

Amgen respects patients and customers and takes the protection of their privacy very seriously. Amgen pledges the following:

  • Amgen does not and will not sell or rent your information to marketing companies or mailing list brokers.
  • Amgen is careful to only collect and/or use personal identifiable information for the purposes stated in this Authorization and as necessary to provide the services and/or programs the patient or customer chooses to enroll into.
  • Amgen practices are consistent with federal and state privacy laws, including HIPAA.
  • Amgen program enrollment is voluntary and always provides patients with an easy option to cancel participation.

Uses and Disclosure of Personal Information

I authorize Amgen and its contractors and business partners (“Amgen”) to use and/or disclose my personal information, including my personal health information, only for the following purposes:

  • To operate, administer, enroll me in, and/or continue my participation in Amgen’s Otezla SupportPlus™ program or any other Amgen-affiliated patient support services and activities related to my condition or treatment (for example, co-pay card programs, reimbursement assistance programs, drug coverage verification, nurse educator services, adherence program and disease management support);
  • To contact, with my permission, my doctor and the rest of my health care team and share with them my health information that may be useful for my care;
  • To provide me with informational and promotional materials relating to Amgen products and services, and/or my condition or treatment; and/or
  • To improve, develop, and evaluate products, services, materials and programs related to my condition or treatment.

In order for Amgen to provide me with the services and/or programs described above, Amgen needs to collect and use my personal information, including my personal health information. I understand that my personal health information may include any information, in electronic or physical form, in the possession of or derived from a health care provider, health care plan, pharmacy, pharmaceutical company, laboratory and/or their contractor (“Health Care Provider”). This may include select information from or about my medical history and general health, my health care plan benefits, payment limits or restrictions covered by my health care plan policy, and/or my adherence to my treatment.

I authorize my Health Care Providers to disclose my personal health information to Amgen, and between themselves, as necessary, but only for the purposes stated above in this Authorization. I understand that certain of my Health Care Providers (such as pharmacies and specialty pharmacies) may receive remuneration from Amgen in exchange for disclosing my personal health information and/or for using my information to contact me with communications about Amgen products which have been prescribed to me (for example medication reminder programs) and other patient support services.

Expiration, Right to Obtain a Copy and Right to Cancel

I understand that by signing this form, I authorize my Health Care Providers or others who might hold my health information to only release it to Amgen employees, as well as to its contractors and business partners, who are performing the services set forth in this Authorization. I also understand I am authorizing my personal information, including my personal health information, to be used for the purposes described above. I understand and agree that by signing below, I am authorizing those who rely on this Authorization to release my personal health information for the earlier of five (5) years or until my participation in the program ends through my cancellation, unless a shorter time period is required by state law.

I understand that I can obtain a copy of this Authorization or cancel this Authorization at any time by calling Amgen at 1-844-468-3952 or by writing to PO BOX 13185, La Jolla, California, 92039. If I cancel my consent, I will no longer qualify for the services described. I also understand that if a Health Care Provider is disclosing my personal health information to Amgen on an authorized on-going basis, my cancellation with Amgen will be effective with respect to any such Health Care Providers as soon as they receive notice of my cancellation.

No Effect on Treatment

I understand I do not have to sign this Authorization and that my enrollment in any of the services and/or programs described above is entirely voluntary. I understand that Amgen, as well as Health Care Providers, cannot require me, as a condition of having access to medications, prescription drugs, treatment or other care, to sign this Authorization. Federal Law (including HIPAA) requires a signed authorization in order for Amgen to collect this information from my Health Care Providers. I understand I cannot participate in the listed services and/or programs without signing this Authorization or an equivalent authorization with my Health Care Providers.

Information Received from Health Care Providers

I understand that once my personal health information has been disclosed to Amgen, federal privacy laws may no longer apply and protect it from further disclosure. Amgen agrees, however, to protect my personal health information by only using and disclosing it as stated in the Authorization or as otherwise allowed or required by law.

Authorization to Contact

I understand and consent to Amgen contacting me using the contact information provided in this form to enroll me in, operate, and administer Amgen patient support services and/or programs as described above other than promotional communications by telephone or SMS/text (which I can separately opt-in below). I understand that the operation and administration of certain of these services and/or programs may require that Amgen contact me by telephone or SMS/text.

Applicable if healthcare provider is assisting.

By clicking the "I agree" button, I represent and am electronically indicating that the patient read and understood Amgen's Patient Authorization (above in its full text) and that I am acknowledging the patient's consent on their behalf. I further represent that I received consent from the patient to disclose their personal health information to Amgen and its contractors and business partners for them to use and share the personal information the patient provided for the purposes described within the Patient Authorization. A copy of the Patient Authorization will be provided to the patient via email. By clicking the “I disagree” button below, the patient’s activation and enrollment into Amgen SupportPlus will be discontinued.


By clicking the “I accept” button, I am electronically indicating that I have read and understood Amgen's Patient Authorization (above in its full text), that I am legally authorized to consent, and that I am providing my consent as the patient or the patient's legal guardian for Amgen and its contractors and business partners to use and share the personal information I provide for the purposes described within the Patient Authorization. By clicking “Cancel” below, my activation and enrollment into Otezla SupportPlus™ will be discontinued.


Voicemail Consent

I give Amgen permission to leave a voice message that refers to Otezla and Otezla SupportPlus™ by name and that may include personal health information about my condition or treatment.


Market Research Consent

Amgen may contact me using the contact information provided in this form for participation in market research activities associated with Amgen's products, services and/or my condition or treatment.

Please verify that you are not a robot.
Processing

Not ready to sign up?
We can remind you! Simply enter your e-mail below, and choose the date on which you’d like to be reminded.

Ways to save on treatment

Regardless of what type of insurance (or lack of insurance) you have, we’re committed to helping you find ways to save on Otezla.

Private, employer-based, or commercially insured

The majority of people pay $0 a month for Otezla. Wondering if you qualify? Fill out and submit the form above or call 1-844-4OTEZLA.

Even if you have health insurance through your employer, you’re eligible to pay $0 each month for Otezla.

Covered by Medicare or Medicaid

If you have Medicare or Medicaid coverage, our team of Insurance Solutions Specialists can assist you with any questions you may have about your plan. Our team is knowledgeable in Medicaid and can also review the Medicare Part D plan phases to help you understand what you can anticipate. To speak with a specialist, call Otezla SupportPlus at 1-844-4OTEZLA.

Uninsured or underinsured

If you do not have insurance or are underinsured, the Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost. To learn more, call Otezla SupportPlus at 1-844-4OTEZLA.

*Summary of Terms and Conditions

It is important that every patient read and understand the full Amgen® SupportPlus Co-Pay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety. Please visit www.AmgenSupportPlus.com for full Terms and Conditions.

As further described below, in general:

  • The Amgen SupportPlus Co-Pay Card is open to patients with commercial insurance that covers an Amgen SupportPlus product, regardless of financial need. The program is not valid for patients whose prescription for an Amgen SupportPlus product is paid for in whole or in part by Medicare, Medicaid, or any other federal or state healthcare program. It is not valid for cash paying patients or where prohibited by law. (See ELIGIBILITY section in full Terms & Conditions.)
  • The Amgen SupportPlus Co-Pay Card may help lower your Amgen SupportPlus product out-of-pocket medication costs. Out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of the product. The Amgen SupportPlus Co-Pay Card provides support up to the Maximum Program Benefit or Patient Total Program Benefit. If a patient's commercial insurance plan imposes different or additional requirements on patients who receive Amgen SupportPlus Co-Pay Card benefits, Amgen has the right to modify or eliminate those benefits. Whether you are eligible to receive the Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your Amgen SupportPlus Representative to help you understand eligibility for the Amgen SupportPlus Co-Pay Card, whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-833-44AMGEN (1-833-442-6436). (See PROGRAM BENEFITS section in full Terms & Conditions.)
  • Amgen SupportPlus patient may pay as little as $0 out-of-pocket for each prescription fill, dose or cycle of the Amgen SupportPlus product.
  • Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient until the Amgen payments have reached either the Maximum Program Benefit and/or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed this limit. Please ask your Amgen SupportPlus Support Representative to help you understand eligibility for the Amgen SupportPlus Co-Pay Card by calling 1-833-44AMGEN (1-833-442-6436). (See PROGRAM DETAILS section in full Terms & Conditions.)

For Otezla® (apremilast) patients only:

  • Bridge to Commercial Coverage Offer: If the patient's health plan requires a prior authorization or if patient experiences a delay in obtaining approval for Otezla® (apremilast), the patient can receive Otezla free for up to twelve (12) prescription fills within twelve (12) months from the date of the first prescription filled under the Bridge to Commercial Coverage Offer while pursuing approval from patient's health plan. No purchase necessary. Once Otezla is approved by the patient's health plan, the patient is no longer eligible for the Bridge to Commercial Coverage Offer.
    • Ongoing eligibility after the first three (3) fills requires that the patient has a prior authorization or medical exception denied within ninety (90) days of first use of this offer. Once insurance approval is obtained, patient is no longer eligible for this offer.
    • This is a one-time offer and patients are ineligible to re-enroll.
  • See PROGRAM DETAILS section in full Terms & Conditions.

Otezla® Co-Pay Card Terms and Conditions

I. ELIGIBILITY

*Eligibility Criteria: Subject to program limitations and terms and conditions, the Amgen SupportPlus Co-Pay Card is open to patients who have been prescribed an Amgen SupportPlus product and who have commercial or private insurance that covers an Amgen SupportPlus product, including plans available through state and federal plans commonly referred to as “healthcare exchanges plans”. This program helps eligible patients cover out-of-pocket medication costs related to an Amgen SupportPlus product, up to program limits. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of an Amgen SupportPlus product. There is no income requirement to participate in this program.

This offer is not valid for patients whose prescription for an Amgen SupportPlus product is paid for in whole or in part by Medicare, Medicaid, or any other federal or state healthcare program. It is not valid for cash-paying patients or where prohibited by law. A patient is considered cash-paying where the patient has no insurance coverage for an Amgen SupportPlus product or where the patient has commercial or private insurance but Amgen in its sole discretion determines the patient is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Amgen SupportPlus product prescription. This offer is only valid in the United States, Puerto Rico, and the US territories.

II. PROGRAM BENEFITS

The Amgen SupportPlus Co-Pay Card also may modify the benefit amount, unilaterally determined by Amgen in its sole discretion, to satisfy the out-of-pocket cost sharing requirement for any patient whose plan or plan agent (including, but not limited to, a Pharmacy Benefit Manager (PBM)) requires enrollment in the Amgen SupportPlus Co-Pay Card as a condition of the plan or PBM waiving some or all of an otherwise applicable patient out-of-pocket cost sharing amount. These programs are often referred to as co-pay maximizer programs. If you believe your commercial insurance plan may have such limitations, please contact Amgen SupportPlus Support at 1-833-44AMGEN (1-833-442-6436). Health plans and Pharmacy Benefit Managers are prohibited from enrolling or assisting in the enrollment of patients in the Amgen SupportPlus Co-Pay Card. The patient, or his/ her legal representative, must personally enroll in the Amgen SupportPlus Co-Pay Card in order to be eligible for program benefits.

If at any time a patient begins receiving coverage for medications under any federal, state, or government healthcare program (including but not limited to Medicare, Medicaid, TRICARE, Department of Defense, or Veteran Affairs programs), the patient will no longer be able to use this card and you must contact Amgen SupportPlus at 1-833-44AMGEN (1-833-442-6436) (Monday through Friday, from 8 am to 8 pm ET) to stop your participation in this program.

Patients may not seek reimbursement for the value received from the Amgen SupportPlus Co-Pay Card from any third-party payers, including a flexible spending account or healthcare savings account. Participating in this program means that you are ensuring you comply with any required disclosure regarding your participation in the Amgen SupportPlus Co-Pay Card of your insurance carrier or pharmacy benefit manager. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.

III. PROGRAM DETAILS

For all eligible patients the Amgen SupportPlus Co-Pay Card offers:

  • A program benefit that covers the patient's eligible out-of-pocket medication costs for the Amgen SupportPlus product (co-pay, deductible, or co-insurance) on behalf of the patient, up to a Maximum Program Benefit determined by the program per calendar year. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of an Amgen SupportPlus product.
  • Amgen SupportPlus patients may pay as little as $0 out-of-pocket for each prescription fill, dose or cycle.

For Otezla® (apremilast) patients only:

  • Bridge to Commercial Coverage Offer: If the patient's health plan requires a prior authorization or if patient experiences a delay in obtaining approval for Otezla® (apremilast), the patient can receive Otezla free for up to twelve (12) prescription fills within twelve (12) months from the date of the first prescription filled under the Bridge to Commercial Coverage Offer while pursuing approval from patient's health plan. No purchase necessary. Once Otezla is approved by the patient's health plan, the patient is no longer eligible for the Bridge to Commercial Coverage Offer.
    • Ongoing eligibility after the first three (3) fills requires that the patient has a prior authorization or medical exception denied within ninety (90) days of first use of this offer. Once insurance approval is obtained, patient is no longer eligible for this offer.
    • This is a one-time offer and patients are ineligible to re-enroll.

Maximum Program Benefit, Patient Total Program Benefit, Benefits May Change, End or Vary Without Notice: The program provides up to a Maximum Program Benefit of assistance to reduce a patient's out-of-pocket medication costs that Amgen will provide per patient for each calendar year, which must be applied to the Amgen SupportPlus patient's out-of-pocket costs (co-pay, deductible, or co-insurance and annual out-of-pocket maximum). Patient Total Program Benefit amounts are unilaterally determined by Amgen in its sole discretion and will not exceed the Maximum Program Benefit. The Patient Total Program Benefit may be less than the Maximum Program Benefit, depending on the terms of a patient's plan, and may vary among individual patients covered by different plans, based on factors determined solely by Amgen, to ensure all programs funds are used for the benefit of the patient. Each patient is responsible for costs above the Patient Total Program Benefit amounts. Please ask your Amgen SupportPlus Support Representative to help you understand whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-833-44AMGEN (1-833-442-6436). Participating patients are solely responsible for updating Amgen with changes to their insurance including, but not limited to, initiation of insurance provided by the government, the addition of any coverage terms that do not apply Amgen SupportPlus Co-Pay Card benefits to reduce a patient's out-of-pocket costs, such as accumulator adjustment benefit design or a co-pay maximization program. Participating patients are responsible for providing Amgen with accurate information necessary to determine program eligibility. By accepting payments from Amgen made on behalf of participating patients, participating PBMs and Plans likewise are responsible for providing Amgen with accurate information regarding patient eligibility.

Patients may use the card every time they receive a dose or cycle of the Amgen SupportPlus product up to the Maximum Program Benefit or Patient Total Program Benefit. Benefits reset each calendar year. Re-enrollment in the program is required at regular intervals. Patients may continue in the program as long as patient re-enrolls as required by Amgen and continues to meet all of the program’s eligibility requirements during participation in the program. Patients can enroll/reenroll by calling 1-833-44AMGEN (1-833-442-6436).

 

Important Safety Information

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause allergic reactions, sometimes severe. Stop using Otezla and call your healthcare provider or seek emergency help right away if you develop any of the following symptoms of a serious allergic reaction: trouble breathing or swallowing, raised bumps (hives), rash or itching, swelling of the face, lips, tongue, throat or arms.

Otezla can cause severe diarrhea, nausea, and vomiting, especially within the first few weeks of treatment. Use in elderly patients and the use of certain medications with Otezla appears to increase the risk of complications from having severe diarrhea, nausea, or vomiting. Tell your doctor if any of these conditions occur.

Otezla is associated with an increase in depression. In clinical studies, some patients reported depression, or suicidal behavior while taking Otezla. Some patients stopped taking Otezla due to depression. Before starting Otezla, tell your doctor if you have had feelings of depression, or suicidal thoughts or behavior. Be sure to tell your doctor if any of these symptoms or other mood changes develop or worsen during treatment with Otezla.

Some patients taking Otezla lost body weight. Your doctor should monitor your weight regularly. If unexplained or significant weight loss occurs, your doctor will decide if you should continue taking Otezla.

Some medicines may make Otezla less effective, and should not be taken with Otezla. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines.

The most common side effects of Otezla include diarrhea, nausea, upper respiratory tract infection, tension headache, and headache. These are not all the possible side effects with Otezla. Ask your doctor about other potential side effects. Tell your doctor about any side effect that bothers you or does not go away.

Tell your doctor if you are pregnant, planning to become pregnant or planning to breastfeed.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.

Please click here for the Full Prescribing Information for Otezla.

APPROVED USES

Otezla® (apremilast) is a prescription medicine used to treat adult patients with:

  • Plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
  • Active psoriatic arthritis.
  • Oral ulcers associated with Behçet’s Disease.
Important Safety Information

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause allergic reactions, sometimes severe. Stop using Otezla and call your healthcare provider or seek emergency help right away if you develop any of the following symptoms of a serious allergic reaction: trouble breathing or swallowing, raised bumps (hives), rash or itching, swelling of the face, lips, tongue, throat or arms.

Sign up for support

Information about paying for Otezla

 

You are now leaving otezla.com and going to Facebook

The content of the linked site is the sole responsibility of the site provider. Amgen Corporation does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to otezla.com.

You are now leaving otezla.com and going to Instagram

The content of the linked site is the sole responsibility of the site provider. Amgen Corporation does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to otezla.com.

You are now leaving otezla.com and going to Youtube

The content of the linked site is the sole responsibility of the site provider. Amgen Corporation does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to otezla.com.

You are now leaving otezla.com and going to Amgen.com

Are you sure you want to do this?

You are now leaving otezla.com and going to Amgen’s “Contact Us” page

Are you sure you want to do this?

You are now leaving otezla.com and going to www.fda.gov/medwatch

The content of the linked site is the sole responsibility of the site provider. Amgen Inc. does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to otezla.com.